News of teaming up with a big name for the development of a potential anti-cancer treatment has unexpectedly raised the value of shares in Silence Therapeutics.

Yes, the shares in Silence Therapeutics have gone up by almost 8 percent today after the fact of its teaming up with Australia's MiReven came out. According to the statements from Silence, the company has plans to use the therapeutic mimic of its partner's miR-7 molecule to combine it with the UK biotechnology group's AtuPLEX, DACC and DBTC delivery systems.

Further, the procedure will run test tube and animal studies over the formulated miR-7 for which the pair is paying an undisclosed fee.

Explaining about their decision, Mr. Klaus Giese, Chief Scientific Officer of Silence, said: "We are delighted to be collaborating with MiReven. This is the fourth collaboration that we have recently signed to explore the use of Silence's delivery technologies for microRNAs".

He added that the pair is aiming to control or shut down the faulty genes in the patient's body with the `gene silencing' i. e. siRNA treatment, which can efficiently tackle cancers and all the other diseases that till now have not been introduced with any traditional chemistry and biotechnology methods.